Bio-Rad Laboratories (BIO) Non-Current Deferred Tax Liability (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $881.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 4.88% year-over-year to $881.8 million; the TTM figure through Mar 2026 stood at $881.8 million (up 4.88% YoY), while the FY2025 annual figure was $1.1 billion, up 29.51% from the prior year.
• Non-Current Deferred Tax Liability declined to $881.8 million in Q1 2026 per BIO's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.0 billion in Q1 2022 and bottomed at $818.0 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $1.3 billion across 5 years, with a median of $1.4 billion in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability plunged 58.41% — and 2025, when it climbed 29.51%.
• Bio-Rad Laboratories' Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then decreased by 14.43% to $1.6 billion in 2023, then tumbled by 50.24% to $818.0 million in 2024, then gained by 29.51% to $1.1 billion in 2025, then retreated by 16.76% to $881.8 million in 2026.
• Business Quant data shows BIO's Non-Current Deferred Tax Liability at $881.8 million in Q1 2026, $1.1 billion in Q4 2025, and $872.6 million in Q3 2025.